Celmatix Company

Celmatix is a next-generation women’s health company transforming the way women and their physicians leverage genomics and data to make more informed, proactive reproductive health decisions. Their products include Polaris, Fertilome genetic test and MyFertility Compass. Celmatix's lead program aims to protect the ovary from chemotherapy-induced ovarian failure (CIOF). For the 1.9 million pre-menopausal women diagnosed with cancer, the need is critical, urgent, and unmet.

Estimated Revenue: $10M to $50M
Funding Status: Early Stage Venture
Headquarters: New York, New York, United States
Total Funding: $53,660,000
Last Funding Date: 2019-04-01
Investors Number: 7
Number Of Exists: Venture - Series Unknown
Founded Date: 01-01-2009
Technology: Longevity FemTech
Industry: Reproductive Health & Contraception
Last Funding Type: Venture - Series Unknown
Investor Type: Company
Investment Stage: N/A
Employee Number: 11-50